Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany.
Schmidt D, Kollan C, Fätkenheuer G, Schülter E, Stellbrink HJ, Noah C, Jensen BE, Stoll M, Bogner JR, Eberle J, Meixenberger K, Kücherer C, Hamouda O, Bartmeyer B; ClinSurv-HIV Drug Resistance Study Group in CHAIN. Schmidt D, et al. Among authors: fatkenheuer g. PLoS One. 2014 Aug 22;9(8):e104474. doi: 10.1371/journal.pone.0104474. eCollection 2014. PLoS One. 2014. PMID: 25148412 Free PMC article.
Trends of prevalence of primary HIV drug resistance in Germany.
Sagir A, Oette M, Kaiser R, Däumer M, Fätkenheuer G, Rockstroh JK, Knechten H, Schmutz G, Hower M, Emmelkamp J, Pfister H, Häussinger D; RESINA Study Team. Sagir A, et al. Among authors: fatkenheuer g. J Antimicrob Chemother. 2007 Oct;60(4):843-8. doi: 10.1093/jac/dkm274. Epub 2007 Aug 22. J Antimicrob Chemother. 2007. PMID: 17715124
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, Fätkenheuer G, Khoo SH, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS. Wyen C, et al. Among authors: fatkenheuer g. J Antimicrob Chemother. 2008 Apr;61(4):914-8. doi: 10.1093/jac/dkn029. Epub 2008 Feb 14. J Antimicrob Chemother. 2008. PMID: 18281305 Free PMC article.
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. Fätkenheuer G, et al. N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154. N Engl J Med. 2008. PMID: 18832245 Free article.
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
Antiretroviral Therapy Cohort Collaboration (ART-CC); Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Antiretroviral Therapy Cohort Collaboration (ART-CC), et al. Among authors: fatkenheuer g. Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468. Clin Infect Dis. 2009. PMID: 19275498 Free PMC article.
Evolution of raltegravir resistance during therapy.
Sichtig N, Sierra S, Kaiser R, Däumer M, Reuter S, Schülter E, Altmann A, Fätkenheuer G, Dittmer U, Pfister H, Esser S. Sichtig N, et al. Among authors: fatkenheuer g. J Antimicrob Chemother. 2009 Jul;64(1):25-32. doi: 10.1093/jac/dkp153. Epub 2009 May 14. J Antimicrob Chemother. 2009. PMID: 19447792
548 results